billHR4710•Wednesday, July 23, 2025Analyzed

No Surprises Act Enforcement Act

Bearish

Impact5/10

UnitedHealth Group ($UNH)Elevance Health ($ELV)Cigna Group ($CI)Humana ($HUM)CVS Health ($CVS)Healthcare

Summary

The 'No Surprises Act Enforcement Act' (HR4710) proposes to significantly increase penalties for health plans and insurers violating balance billing requirements, directly raising compliance costs and legal exposure. This bill, currently in early stages, indicates a future increase in operational expenses and regulatory risk for major health insurance providers. Despite this, major health insurers like UnitedHealth Group ($UNH), Elevance Health ($ELV), Cigna Group ($CI), and Humana ($HUM) have shown positive 7-day price changes, while CVS Health ($CVS) also saw a 4.48% increase.

Key Takeaways

1.HR4710 proposes to increase penalties for health plans violating balance billing rules, directly raising compliance costs for insurers.
2.Major health insurers like UnitedHealth Group ($UNH), Elevance Health ($ELV), Cigna Group ($CI), Humana ($HUM), and CVS Health ($CVS) are structural losers due to increased regulatory risk and potential fines.
3.The bill is in early committee stages, but a companion bill (S2420) in the Senate suggests potential for future legislative action.

Market Implications

The 'No Surprises Act Enforcement Act' (HR4710) presents a long-term bearish outlook for health insurance providers by increasing their operational expenses and regulatory exposure. While the bill is in its early stages, its eventual passage would directly reduce profitability for companies like UnitedHealth Group ($UNH), Elevance Health ($ELV), The Cigna Group ($CI), Humana Inc. ($HUM), and CVS Health ($CVS). Despite this, recent market performance shows these tickers experiencing positive 7-day changes: $UNH at $281.36 (+7.48%), $ELV at $302.61 (+6.26%), $CI at $275.69 (+6.82%), $HUM at $182.65 (+10.03%), and $CVS at $73.28 (+4.48%). This suggests the market has not yet fully incorporated the potential negative impact of this legislation, which is still far from becoming law.

Full Analysis

The 'No Surprises Act Enforcement Act' (HR4710) was introduced in the House on July 23, 2025, and subsequently referred to the Committees on Energy and Commerce, Education and Workforce, and Ways and Means. This bill aims to amend existing acts to increase penalties for group health plans and health insurance issuers that violate balance billing requirements. The bill is currently in an early stage of the legislative process, having only been referred to committees. This legislation does not involve direct funding or appropriations. Instead, it modifies existing regulations by increasing the financial penalties for non-compliance. Specifically, it proposes to amend the Public Health Service Act, the Employee Retirement Income Security Act of 1974, and the Internal Revenue Code of 1986 to allow for penalties of up to $10,000 for each failure to comply with specified balance billing provisions. This mechanism directly impacts the operational costs and regulatory risk profiles of health insurance providers. Structural losers under this proposed legislation are major health insurance providers, including UnitedHealth Group ($UNH), Elevance Health ($ELV), The Cigna Group ($CI), and Humana Inc. ($HUM). These companies would face increased compliance costs and greater financial exposure due to the higher penalties for balance billing violations. CVS Health ($CVS), which operates Aetna, would also be negatively impacted. Despite the long-term negative implications of this bill, recent market data shows that $UNH, $ELV, $CI, and $HUM have experienced positive 7-day changes of +7.48%, +6.26%, +6.82%, and +10.03% respectively. $CVS also saw a +4.48% 7-day change. These short-term gains suggest that the market has not yet fully priced in the potential future regulatory burdens from this early-stage bill. As of today, April 7, 2026, the bill is in the committee review stage. For the bill to progress, it must be considered and passed by the referred committees, then by the full House, and subsequently introduced and passed by the Senate (potentially as the companion bill S2420). Given its early stage, significant legislative steps remain, and the timeline for potential enactment is uncertain. The presence of a companion bill (S2420) in the Senate indicates bipartisan and bicameral interest in the issue, which could facilitate its eventual passage.